Nano Carrier IR report 2017

7/12

NakatomiDr. SaijoNakatomiNakatomiccordingly even wen te endoint was not to e met it is uite common to conduct additional studies reeatedly wit te same drug. n tis way clinical studies are imortant and it is an etremely difcult endeavor tat must e conducted wile solving various rolems and wile a long time and large eenses are involved te future of cancer treatment tat will overcome tese rolems awaits.e are develoing te accurate delivery of drugs targeted to te tumor itself. at do you tin aout te future of small molecular drugs and e role of *2 tat uses a cytotoic antitumor drug and molecular targeting drugs for driver mutations*3 is very imortant and elieve tey will continue to e necessary in cancer cemoteray for te future as well. our comanys tecnology tat will ring aout canges to in articular is igly anticiated tat it will e an imortant layer in cancer treatment.ese words are very encouraging for us. an you very muc. ou ave focused on cooerating wit international scientic societies and you are conducting training seminars for clinical oncology togeter wit foreign scientic societies. elieve you now very well te differences etween aan and uroe te .. in clinical studies. snt te time until aroval of a new drug in aan very slow comared to in uroe and te ..Dr. SaijoNakatomiDr. SaijoNakatomin aan te situation tat aroval of new anticancer agents was delayed and te necessary and effective new drugs could not e used continued for a long time. t taes an average of years for a new drug to e aroved in aan after it is aroved elsewere in te world and comared wit uroe and te nited tates tere is a lag of two and a alf years. ere are tree reasons for wy te aroval of new drug was delayed. irst is te delay in te start of clinical stud-ies y te comany second is te delay in te recruitment of atients for clinical studies and te last is te delay in te review y te armaceuticals and edical evices gency . ince te delay in te review as een imroved after directives were issued y te inistry of ealt aour and elfare and and researcers are also aware te imor-tance of recruitment it as now ecome ossile to arove witout delay te imortant drugs suc as wen no oter treatment is availale.ere are still various rolems tat must e imroved in clinical studies in aan .s you ointed out it is still difcult in aan to say tat te imortance of clinical studies is fully understood. ost stan-dard teraies are estalised in and introduced from foreign countries. any clinical studies are comliant wit foreign studies and incentives for clinical researcers are not suf-cient. nless we mae efforts to otain our own results of clini-cal studies in aan in te sort term we are going to fall eind te world in all asects in te future. is is recisely wy esecially for aanorigin drugs oe armaceutical comanies to give te igest riority to clinical develoment in aan and to egin ase clinical studies in aan rst. wis te government ealtcare rofessionals atients and teir families armaceutical comanies and te media to deeen teir understanding of clinical studies and to com-ine teir strengts toward te develoment of etter cancer treatments.e will continue to callenge for te develoment of suerior anticancer drugs. an you very muc for roviding us wit your imortant oinions today. 7For enhancement of clinical studies in Japan